Robert M. Knabb

5.6k total citations · 1 hit paper
98 papers, 4.3k citations indexed

About

Robert M. Knabb is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Genetics. According to data from OpenAlex, Robert M. Knabb has authored 98 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Hematology, 46 papers in Cardiology and Cardiovascular Medicine and 20 papers in Genetics. Recurrent topics in Robert M. Knabb's work include Blood Coagulation and Thrombosis Mechanisms (65 papers), Atrial Fibrillation Management and Outcomes (31 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (20 papers). Robert M. Knabb is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (65 papers), Atrial Fibrillation Management and Outcomes (31 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (20 papers). Robert M. Knabb collaborates with scholars based in United States, Germany and Sweden. Robert M. Knabb's co-authors include Ruth R. Wexler, Pancras C. Wong, Donald Pinto, Joseph M. Luettgen, Patrick Y. S. Lam, Charles A. Kettner, Richard Alexander, Lawrence J. Mersinger, Mimi L. Quan and Kan He and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Circulation.

In The Last Decade

Robert M. Knabb

98 papers receiving 4.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients

2011 401 citations Robert M. Knabb et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Robert M. Knabb	1.9k	1.3k	1.0k	1.0k	751	98	4.3k
Donald Pinto	1.6k 0.8×	672 0.5×	1.1k 1.1×	720 0.7×	513 0.7×	58	3.5k
Uma Sinha	1.2k 0.6×	743 0.6×	812 0.8×	237 0.2×	746 1.0×	109	2.9k
Elisabeth Perzborn	2.8k 1.5×	841 0.7×	2.0k 1.9×	216 0.2×	614 0.8×	70	4.4k
Joseph M. Luettgen	999 0.5×	838 0.7×	491 0.5×	736 0.7×	460 0.6×	72	2.5k
Joseph A. Jakubowski	7.1k 3.8×	1.0k 0.8×	2.2k 2.1×	586 0.6×	456 0.6×	145	8.6k
Ulf G. Eriksson	1.4k 0.8×	523 0.4×	1.2k 1.1×	150 0.1×	447 0.6×	103	3.2k
Donglu Zhang	1.5k 0.8×	202 0.2×	935 0.9×	273 0.3×	1.4k 1.9×	122	5.0k
Norbert Hauel	909 0.5×	290 0.2×	452 0.4×	430 0.4×	551 0.7×	31	2.1k
Sven Nylander	1.4k 0.8×	415 0.3×	569 0.6×	112 0.1×	431 0.6×	52	2.6k
Frank LaCreta	1.7k 0.9×	177 0.1×	863 0.8×	111 0.1×	1.1k 1.5×	110	4.5k

Countries citing papers authored by Robert M. Knabb

Since Specialization

Citations

This map shows the geographic impact of Robert M. Knabb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert M. Knabb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert M. Knabb more than expected).

Fields of papers citing papers by Robert M. Knabb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert M. Knabb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert M. Knabb. The network helps show where Robert M. Knabb may publish in the future.

Co-authorship network of co-authors of Robert M. Knabb

This figure shows the co-authorship network connecting the top 25 collaborators of Robert M. Knabb. A scholar is included among the top collaborators of Robert M. Knabb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert M. Knabb. Robert M. Knabb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Xiaojun, Peter W. Glunz, Wen Jiang, et al.. (2013). Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF–FVIIa inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(6). 1604–1607. 7 indexed citations

Priestley, E. Scott, Jinglan Zhou, Jiacheng Zhou, et al.. (2013). Discovery and gram-scale synthesis of BMS-593214, a potent, selective FVIIa inhibitor. Bioorganic & Medicinal Chemistry Letters. 23(8). 2432–2435. 23 indexed citations

Pinto, Donald, Jennifer X. Qiao, & Robert M. Knabb. (2012). The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review. Expert Opinion on Therapeutic Patents. 22(6). 645–661. 12 indexed citations

Wang, Jessie J., Robert M. Knabb, Puneet Mohan, & Yu Chen Barrett. (2010). Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis. 105(1). 181–189. 21 indexed citations

Wong, Pancras C., Earl J. Crain, Ruth R. Wexler, et al.. (2008). Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. Journal of Thrombosis and Haemostasis. 6(5). 820–829. 246 indexed citations

Qiao, Jennifer X., Kan He, Pancras C. Wong, et al.. (2008). Highly efficacious factor Xa inhibitors containing α-substituted phenylcycloalkyl P4 moieties. Bioorganic & Medicinal Chemistry Letters. 19(2). 462–468. 14 indexed citations

Zhang, Donglu, Nirmala Raghavan, Shiang-Yuan Chen, et al.. (2007). Reductive Isoxazole Ring Opening of the Anticoagulant Razaxaban Is the Major Metabolic Clearance Pathway in Rats and Dogs. Drug Metabolism and Disposition. 36(2). 303–315. 46 indexed citations

Varnes, Jeffrey, Dean A. Wacker, Donald Pinto, et al.. (2007). Structure–activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(2). 749–754. 29 indexed citations

Qiao, Jennifer X., Chong‐Hwan Chang, Daniel L. Cheney, et al.. (2007). SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa. Bioorganic & Medicinal Chemistry Letters. 17(16). 4419–4427. 29 indexed citations

10.

Qiao, Jennifer X., Tammy C. Wang, Daniel L. Cheney, et al.. (2007). Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications. Bioorganic & Medicinal Chemistry Letters. 17(18). 5041–5048. 17 indexed citations

11.

Qiao, Jennifer X., Xuhong Cheng, Joanne M. Smallheer, et al.. (2006). Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues. Bioorganic & Medicinal Chemistry Letters. 17(5). 1432–1437. 18 indexed citations

12.

Smallheer, Joanne M., Richard Alexander, Jianmin Wang, et al.. (2004). SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa. Bioorganic & Medicinal Chemistry Letters. 14(21). 5263–5267. 30 indexed citations

13.

Lam, Patrick Y. S., Charles G. Clark, William J. Calhoun, et al.. (2003). Discovery of 3-Amino-4-Chlorophenyl P1 as a novel and potent benzamidine mimic via solid-phase synthesis of an isoxazoline library. Bioorganic & Medicinal Chemistry Letters. 13(10). 1795–1799. 23 indexed citations

14.

Wong, Pancras C., Earl J. Crain, Robert M. Knabb, et al.. (2000). Nonpeptide Factor Xa Inhibitors II. Antithrombotic Evaluation in a Rabbit Model of Electrically Induced Carotid Artery Thrombosis. Journal of Pharmacology and Experimental Therapeutics. 295(1). 212–218. 25 indexed citations

15.

Dominguez, Celia, Qi Han, Richard Alexander, et al.. (1999). Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors. Bioorganic & Medicinal Chemistry Letters. 9(7). 925–930. 6 indexed citations

16.

Fevig, John M., Pieter F. W. Stouten, Robert M. Knabb, et al.. (1999). Preparation of pyrrolidine and isoxazolidine benzamidines as potent inhibitors of coagulation factor Xa. Bioorganic & Medicinal Chemistry Letters. 9(8). 1195–1200. 11 indexed citations

17.

Galemmo, Robert A., Thomas Maduskuie, Celia Dominguez, et al.. (1998). The de novo design and synthesis of cyclic urea inhibitors of factor Xa: Initial sar studies. Bioorganic & Medicinal Chemistry Letters. 8(19). 2705–2710. 15 indexed citations

18.

Fevig, John M., Joseph Cacciola, Richard Alexander, et al.. (1998). Rational design of boropeptide thrombin inhibitors: β,β-dialkyl-phenethylglycine P2 analogs of DuP 714 with greater selectivity over complement factor I and an improved safety profile. Bioorganic & Medicinal Chemistry Letters. 8(3). 301–306. 32 indexed citations

19.

Knabb, Robert M., Steven R. Bergmann, Keith A.A. Fox, & Burton E. Sobel. (1987). The temporal pattern of recovery of myocardial perfusion and metabolism delineated by positron emission tomography after coronary thrombolysis.. PubMed. 28(10). 1563–70. 34 indexed citations

20.

Knabb, Robert M., Thomas Rosamond, Keith A.A. Fox, Burton E. Sobel, & Steven R. Bergmann. (1986). Enhancement of salvage of reperfused ischemic myocardium by diltiazem. Journal of the American College of Cardiology. 8(4). 861–871. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact